A Monte Carlo simulation of advanced HIV disease: Application to prevention of CMV infection

Medical Decision Making

Volumn 18, Issue 2 SUPPL., 1998, Pages

  Paltiel, A David ^a   Scharfstein, Julie A ^b   Seage III, George R ^b   Losina, Elena ^b   Goldie, Sue J ^b   Weinstein, Milton C ^b   Craven, Donald E ^b   Freedberg, Kenneth A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

AIDS; Cost effectiveness analysis; Cytomegalovirus infection; HIV infection; Monte Carlo simulation

Indexed keywords

GANCICLOVIR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; SYSTEM ANALYSIS;

EID: 0031901498     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989x98018002s11     Document Type: Article

References (78)

1. Aboulker J, Swart A. Preliminary analysis of the Concorde trial. Lancet. 1993;341:889-90.
2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA. 1996;276:146-54.
3. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA. 1996;275:1329-34.
4. Fischl MA, Richman DD, Grieco MH, and The AIDS Clinical Trials Group. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-91.
5. Fischl MA, Richman DD, Hansen N, and The AZT Collaborative Working Group. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med. 1990;112:727-37.
6. Graham N, Zeger S, Park L, et al. The effects on survival of early treatment of HIV infection. N Engl J Med. 1992;326:1037-42.
7. Harris JE. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987. JAMA. 1990;263:397-401.
8. Lemp GF, Payne SF, Neal D, Temelso T, Rutherford GW. Survival trends for patients with AIDS. JAMA. 1990;263:402-6.
9. Seage G, Oddleifson S, Carr E, et al. Survival with AIDS in Massachusetts 1979-1989. Am J Public Health. 1993;83:72-8.
10. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-9.
11. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270:474-8.
12. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. public Health Rep. 1987;102:5-17.
13. Seage GR, Landers S, Barry MA, Groopman J, Lamb G, Epstein A. Medical care costs of AIDS in Massachusetts. JAMA. 1986;256:3107-9.
14. Arno PS, Shenson D, Siegel NF, Franks P, Lee PR. Economic and policy implications of early intervention in HIV disease. JAMA. 1989;262:1493-8.
15. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med. 1993;329:1922-6.
16. Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR. June 27, 1997; 46(RR-12):1-46.
17. National Alliance of State and Territorial AIDS Directors. The fiscal status of AIDS drug assistance programs: findings from a January 199G national survey of state AIDS directors. Prepared for the United States Health Resources and Services Administration, Division of HIV Services, April 1996.
18. McGinley L. States move to ration promising AIDS drugs. Wall Street Journal. August 22, 199G:B1.
19. Pear R. Expense means many can't get drugs for AIDS. New York Times. February 16, 1997:A1.
20. Schooley RT. Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev Infect Dis. 1990;12:S811-S819.
21. Hirsch MS. Cytomegalovirus and its role in the pathogenesis of acquired immunodeficiency syndrome. Transplant Proc. 1991;23, suppl 3:118-21.
22. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989;320:289-93.
23. Balfour HH. Management of cytomegalovirus disease with antiviral drugs. Rev Infect Dis. 1990;12:S849-S860.
24. Merigan TC, Resta S. Cytomegalovirus: Where have we been and where are we going? Rev Infect Dis. 1990;12, suppl 7: S693-S700.
25. Merigan TC. Treatment of cytomegalovirus infection in the AIDS patient. Transplant Proc. 1991;23, suppl 3:122-5.
26. Polis MA, deSmet MD, Baird BF, et al. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med. 1993;94:175-80.
27. Drug Topics Red Book. Montvale, NJ: Medical Economics, 1996.
28. Spector SA, McKinley GF, Lalezari JP, et al, and the Roche Cooperative Oral Ganciclovir Study Group. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 1996;334:1491-7.
29. Feinberg J, Cooper D, Hurwitz S, for the ACTG204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. Phase III International Study of valaciclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease. Presentation Th.B.300, 11th International Conference on AIDS, 1996, Vancouver, BC, Canada.
30. Brosgart C, Craig C, Hillman D, et al. Final results from a randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease. Presentation Th.B.301, 11th International Conference on AIDS, 1996, Vancouver, BC, Canada.
31. Robbins GK, Cotton DJ. Cost-effectiveness of ganciclovir for prevention of CMV retinitis. Abstract 296, Session 31, 4th Conference on Rctroviruses and Opportunistic Infections. Washington, DC, 1997.
32. Rose DN, Sacks HS. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing. AIDS. 1997;11:883-7.
33. Gold MR, Siegel JR, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Report of the Panel on Costeffectiveness in Health and Medicine. New York: Oxford University Press, 1996.
34. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making. 1985;5:157-77.
35. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Imune Defic Syndr Hum Retrovirol. 1992;5:1069-74.
36. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A, and The Multicentcr AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with HIV Type I. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161-5.
37. Kaplan JE, Masur H, Jaffe HW, Holmes KK. Preventing opportunistic infections in persons infected with HIV. 1997 guidelines. JAMA. 1997;278:337-8.
38. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA. 1993;270:2583-9.
39. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis for Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pnuemocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR. 1992;41(RR-4):1-11.
40. Freedberg KA, Scharfstein JA, Seage GR, et al. The cost-effectiveness of preventing AIDS-rclatcd opportunistic infections. JAMA. 1998;279:130-6.
41. Scharfstein JA, Paltiel AD, Weinstein MC, Freedberg KA. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. Under review.
42. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-8.
43. Multicenter AIDS Cohort Study (MACS). Public Data Set (Release PO4). Springfield, VA: National Technical Information Service, 1995.
44. Laird NM, Ware JH. Random effects model for longitudinal data. Biometrics. 1982;38:963-74.
45. Miller DK, Human SM. Determining transition probabilities. Med Decis Making. 1994;14:52-8.
46. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trial Group Protocol 021. N Engl J Med. 1992;327:1842-8.
47. AIDS Cost and Services Utilization Survey. Public use tapes #4 and #5. #PB94-189891, Springfield, VA: National Technical Information Service, 1991.
48. Hellinger FJ. Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry. 1992;29:356-65.
49. Hellinger FJ, Fleishman JA, Hsia DC. AIDS treatment costs during the last months of life: evidence from the ACSUS. Health Serv Res. 1994;29:569-81.
50. Finkler SA. The distinction between cost and charges. Ann Intern Med. 1982;96:102-9.
51. United States Bureau of the Census. Statistical Abstract of the United States: 1996. 116th ed. Washington, DC, 1996.
52. Paltiel AD, Stinnett AA. AIDS. In: Spilker B (cd). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. New York: Raven, 1996.
53. Tsevat J, Solzan JG, Kuntz K, et al. Health values of patients infected with human immunodeficiency virus. Med Care. 1996;34:44-57.
54. Torrance GW, Boyle MH, Horwood SP. Application of multiattribute utility theory to measure social preferences for health states. Operations Research. 1982;30:1043-69.
55. Stiggelbout AM, Eijkemans MJC, Kiebert GM, et al. The "utility" of the visual analog scale in medical decision making and technology assessment. Int J Technol Assess Health Care. 1996;12:291-8.
56. van Hout B, Bonsel G, Habbema D, van der Maas P. Heart transplantation in the Netherlands; costs, effects, and scenarios. J Health Econ. 1993;12:73-93.
57. de Haes JCJM, de Koning HJ, van Oortmarssen GJ, et al. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991;49:538-44.
58. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioeconomic Planning Science. 1976;10:128-36.
59. ++, Version 2.0 (1995). Microsoft Windows 95, Version 4.00.950 (1996).
60. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model. Am J Public Health. 1987;77:1417-26.
61. Eddy DM, Hasselblad V, McGivney W, Hendee W. The value of mammography screening in women under age 50 years. JAMA. 1988;259:1512.
62. Jager J, Ruitenberg E (eds). AIDS Impact Assessment: Modeling and Scenario Analysis. Amsterdam, The Netherlands: Elsevier, 1992.
63. Pliskin JS, Tell EJ. A dialysis need forecasting model: a retrospective evaluation. Med Decis Making. 1983;3:489-500.
64. Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan FA (ed). Valuing Health Care: Costs, Benefits, and the Effectiveness of Pharmaceuticals and Other Medical Technologies. New York: Cambridge University Press, 1995.
65. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-58.
66. Holtgrave DR, Qualls NL. Threshold analysis and programs for prevention of HIV infection. Med Decis Making. 1995;15:311-7.
67. Kaplan RM, Bush JW. Hoalth-related quality of life measurement for evaluation research and policy analysis. Health Psychol. 1981;1:61-80.
68. Owens DK, Nease RF, Harris RA. Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings (abstr). Med Decis Making. 1993;13:395.
69. Drummond MF, Torrance GW, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med. 1993;37:33-40.
70. Mason J, Drummond MF, Torrance GW. Some guidelines on the use of cost-effectiveness league tables. BMJ. 1993;306:570-2.
71. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In: Sloan FA (ed). Valuing Health Care: Costs, Benefits, and the Effectiveness of Pharmaceuticals and Other Medical Technologies. New York: Cambridge University Press, 1995.
72. 3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Virol. 1991;4:521-31.
73. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA. 1991;266:820-4.
74. Freedberg KA, Cohen CJ, Barber TW. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients uith AIDS: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:275-82.
75. McCarthy B, Wong J, Munoz A, Sonnenberg F. Who should be screened for HIV infection? Arch Intern Med. 1993;153:1107-16.
76. Owens DK, Nease RF, Harris RA. Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med. 1996;156:394-404.
77. Moore RD, Bartlett JG. Combination antiviral therapy in HIV infection: an economic perspective. PharmacoEconomics. 1996;10:109-13.
78. Spector SA, Pilcher M, Lamy P, Hsia K, Wong R, Stempien MJ, and the Roche Cooperative Oral Ganciclovir Study Group. PCR of plasma for cytomegalovirus DNA identifies HIV-infected persons most likely to benefit from oral ganciclovir prophylaxis. Presentation Th.B.302, 11th International Conference on AIDS, 1996, Vancouver, BC, Canada.